

## Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

J. Compston · D. M. Reid · J. Boisdron · M.-L. Brandi ·  
N. Burllet · D. Cahall · P. D. Delmas · W. Dere ·  
J.-P. Devogelaer · L. A. Fitzpatrick · B. Flamion ·  
N. Goel · S. Korte · A. Laslop · B. Mitlak ·  
S. Ormarsdottir · J. Ringe · R. Rizzoli · Y. Tsouderos ·  
T. Van Staa · J.-Y. Reginster

Published online: 4 September 2008

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

### Erratum to: *Osteoporos Int* DOI 10.1007/s00198-008-0670-7

The location of Sanofi-Aventis, the employer of co-author D. Cahall, was incorrectly given as Cincinnati, USA. The true location is Bridgewater, NJ, USA.

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00198-008-0670-7>.

---

J. Compston (✉)  
Department of Medicine,  
University of Cambridge School of Clinical Medicine,  
Cambridge, UK  
e-mail: jec1001@cam.ac.uk

D. M. Reid  
University of Aberdeen Medical School,  
Foresterhill,  
Aberdeen AB25 2ZD, UK

J. Boisdron  
Hoffman-La Roche Ltd,  
Basle, Switzerland

M.-L. Brandi  
Metabolic Bone Unit, Laboratory of Molecular Genetics,  
Department of Internal Medicine, University of Florence,  
Florence, Italy

N. Burllet  
International Osteoporosis Foundation,  
Nyon, Switzerland

D. Cahall  
Sanofi-Aventis,  
Bridgewater, NJ, USA

P. D. Delmas  
Department of Medicine,  
University of Lyon and INSERM Research Unit 831,  
Lyon, France

W. Dere  
Amgen,  
Thousand Oaks, CA, USA

J.-P. Devogelaer  
The Arthritis Unit, Université Catholique de Louvain,  
Brussels, Belgium

L. A. Fitzpatrick  
Medicines Disease Center, GlaxoSmithKline,  
King of Prussia, PA, USA

B. Flamion  
Laboratory of Physiology and Pharmacology,  
University of Namur,  
Namur, Belgium

N. Goel  
Clinical Development, UCB Inc.,  
Smyrna, GA, USA

---

S. Korte  
Novartis Pharma,  
Berne, AG, Switzerland

A. Laslop  
AGES PharmMed,  
Vienna, Austria

B. Mitlak  
Lilly Research Laboratories, Eli Lilly and Company,  
Indianapolis, IN, USA

S. Ormarsdottir  
Icelandic Medicines Control Agency,  
Seltjarnarnes, Iceland

J. Ringe  
West German Osteoporosis Center (WOZ) and Med. Clinic 4 at  
Klinikum Leverkusen, University of Cologne,  
Cologne, Germany

R. Rizzoli  
Division of Bone Diseases,  
WHO Collaborating Centre for Osteoporosis Prevention,  
Department of Rehabilitation and Geriatrics,  
Geneva University Hospitals and Faculty of Medicine,  
Geneva, Switzerland

Y. Tsouderos  
Institut de Recherches Internationales Servier,  
Courbevoie, France

T. Van Staa  
General Practice Research Database,  
Medicines and Healthcare Products Regulatory Agency,  
London, UK

J.-Y. Reginster  
Department of Public Health Sciences, University of Liège, Liège,  
Belgium, Chairman GREES,  
Liège, Belgium